DEFM14A: NeueHealth to be Acquired by NH Holdings in $7.33 Per Share Deal

NeueHealth, Inc. has entered into a definitive agreement to be acquired by NH Holdings 2025, Inc. for $7.33 per share in cash.

Summary

• NeueHealth, Inc. is set to be acquired by NH Holdings 2025, Inc. for $7.33 per share in cash.
• The merger agreement was unanimously approved by the Company Board, acting upon the recommendation of the Special Committee.
• Rollover Holders, owning approximately 64% of the Company Common Stock, Series A Preferred Stock and Series B Preferred Stock, have agreed to contribute their shares to Ultimate Parent.
• NEA has committed to provide equity financing up to $30,000,000 to finance the Merger Consideration.
• The Special Committee determined the Merger Agreement and the transactions contemplated thereby, including the Merger, are fair to, and in the best interests of, the Company and the holders of shares of Company Common Stock.
• The Merger Agreement Proposal requires the affirmative vote of the holders of a majority of the voting power of the outstanding shares of Company Common Stock and Company Preferred Stock.
• The Special Meeting of Stockholders is scheduled for May 7, 2025.
• Lincoln International rendered to the Special Committee its oral opinion, which was subsequently confirmed by delivery of a written opinion, dated December 18, 2024, that the Merger Consideration to be received in the Merger by the Public Stockholders in respect of the shares of Company Common Stock held thereby, other than Excluded Shares and any Dissenting Shares, is fair, from a financial point of view, to the Public Stockholders.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the premium offered to shareholders and the unanimous approval by the Company Board and Special Committee. However, the loss of future potential gains and the delisting of the stock temper the overall sentiment.

Positives

• The Merger Consideration of $7.33 per share represents a premium of approximately 70% to the closing price of the Company Common Stock on December 23, 2024.
• The Merger is not subject to any financing condition.
• The Company Board, acting upon the recommendation of the Special Committee, unanimously determined that the Merger Agreement and transactions contemplated thereby, including the Merger, are fair to, and in the best interests of, the Company and its stockholders.
• Lincoln rendered to the Special Committee its oral opinion, which was subsequently confirmed in writing by delivery of a written opinion, dated December 18, 2024, that the Merger Consideration to be received in the Merger by the Public Stockholders in respect of the shares of Company Common Stock held thereby, other than Excluded Shares and any Dissenting Shares, is fair, from a financial point of view, to the Public Stockholders.

Negatives

• If the Merger Agreement Proposal is not approved by the Companys stockholders or if the Merger is not completed for any other reason, the Companys stockholders will not receive any payment for their shares of Company Common Stock in connection with the Merger.
• If the Merger is completed, the Company Common Stock will be delisted from NYSE, will be deregistered under the Exchange Act and will cease to be publicly traded.

Risks

• The completion of the Merger is subject to the satisfaction or waiver of certain conditions set forth in the Merger Agreement, including the approval of the Merger Agreement Proposal by a Majority of the Outstanding Shares.
• The accompanying proxy statement provides you with more detailed information about the Special Meeting, the Merger Agreement and the transactions contemplated by it, including the Merger.
• In particular, you should read the Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2024, and other risk factors detailed from time to time in the Companys reports filed with the SEC and incorporated by reference in this proxy statement, for risks relating to our business and for a discussion of the risks that you should consider in evaluating the proposed transaction and how it may affect you.

Future Outlook

The Company anticipates that the Merger will be completed in the middle of 2025, assuming timely satisfaction or waiver of necessary closing conditions.

Industry Context

The announcement does not provide specific details on how this announcement relates to broader industry trends or competitors.

Related Party Transactions

• Rollover Holders, owning approximately 64% of the Company Common Stock, Series A Preferred Stock and Series B Preferred Stock, have agreed to contribute their shares to Ultimate Parent.

Stakeholder Impact

• Shareholders will receive $7.33 per share in cash.
• Executive officers and directors may have certain interests in the Merger that are different from, or in addition to, the interests of the Companys stockholders generally.
• Employees face uncertainty regarding their future roles with the company.

Next Steps

• The Company will hold a Special Meeting of Stockholders on May 7, 2025, to vote on the Merger Agreement Proposal.
• The parties will work to obtain necessary regulatory approvals.
• The parties will work to satisfy all other closing conditions outlined in the Merger Agreement.

Key Dates

Keywords

Merger Agreement, NeueHealth, NH Holdings, Acquisition, Stockholders, Merger